StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) stock

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.41+0.01 (+2.12%)

Close on Nov 18, 2026Market cap $113.31MP/E –Yield –

Akebia Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Akebia Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$15.13M, down 2012.3% year over year. For fiscal 2025 it was $23.50M. The highest annual figure on record is $23.50M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$23.50M–
FY2024Dec 31, 2024-$50.47M–
FY2023Dec 31, 2023-$46.26M–
FY2022Dec 31, 2022-$80.78M–
FY2021Dec 31, 2021-$264.50M–
FY2020Dec 31, 2020-$377.83M–
FY2019Dec 31, 2019-$286.29M–
FY2018Dec 31, 2018-$178.16M–
FY2017Dec 31, 2017-$76.67M–
FY2016Dec 31, 2016-$136.46M–
FY2015Dec 31, 2015-$61.51M–
FY2014Dec 31, 2014-$37.94M–
FY2013Dec 31, 2013-$15.93M–
FY2012Dec 31, 2012-$8.52M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.33M-144.9%
Q1 FY2026Mar 31, 2026-$4.70M-134.7%
Q4 FY2025Dec 31, 2025-$8.55M–
Q3 FY2025Sep 30, 2025$4.45M–
Q2 FY2025Jun 30, 2025$14.09M–
Q1 FY2025Mar 31, 2025$13.51M–
Q4 FY2024Dec 31, 2024-$14.31M-1141.3%
Q3 FY2024Sep 30, 2024-$12.51M–
Q2 FY2024Jun 30, 2024-$8.73M–
Q1 FY2024Mar 31, 2024-$14.94M–
Q4 FY2023Dec 31, 2023$1.37M–
Q3 FY2023Sep 30, 2023-$13.04M–
Q2 FY2023Jun 30, 2023-$9.00M-126.4%
Q1 FY2023Mar 31, 2023-$25.60M–
Q4 FY2022Dec 31, 2022-$4.87M–
Q3 FY2022Sep 30, 2022-$50.41M–
Q2 FY2022Jun 30, 2022$34.08M–
Q1 FY2022Mar 31, 2022-$59.58M–
Q4 FY2021Dec 31, 2021-$65.34M–
Q3 FY2021Sep 30, 2021-$54.89M–
Q2 FY2021Jun 30, 2021-$79.34M–
Q1 FY2021Mar 31, 2021-$64.94M–
Q4 FY2020Dec 31, 2020-$85.40M–
Q3 FY2020Sep 30, 2020-$58.10M–
Q2 FY2020Jun 30, 2020-$173.82M–
Q1 FY2020Mar 31, 2020-$59.13M–
Q4 FY2019Dec 31, 2019-$94.89M–
Q3 FY2019Sep 30, 2019-$55.91M–
Q2 FY2019Jun 30, 2019-$59.52M–
Q1 FY2019Mar 31, 2019-$75.97M–
Q4 FY2018Dec 31, 2018-$90.16M-717.1%
Q3 FY2018Sep 30, 2018-$27.84M–
Q2 FY2018Jun 30, 2018-$35.66M–
Q1 FY2018Mar 31, 2018-$24.50M–
Q4 FY2017Dec 31, 2017$14.61M–
Q3 FY2017Sep 30, 2017-$24.18M–
Q2 FY2017Jun 30, 2017-$22.14M–
Q1 FY2017Mar 31, 2017-$44.97M–
Q4 FY2016Dec 31, 2016-$38.04M–
Q3 FY2016Sep 30, 2016-$36.18M–

More Akebia Therapeutics figures

See a number that looks wrong?